新辅助化疗免疫疗法显示主要的病理反应和低复发在头部和部状细胞癌
Shida Yan1,2, Lili Liu3,2, Xing Zhang1,2
1Department of Head and Neck, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.
概括
针对可切除头部和部状细胞癌 (HNSCC) 的新辅助化疗免疫疗法显示出有希望的疗效. 这种治疗方法实现了高病理反应率和低复发率,表明它可能成为新的护理标准.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 头部和部癌症研究研究
背景情况:
- 研究新辅助化疗与PD-1阻断结合用于可切除的HNSCC.
- 评估这种联合治疗模式的疗效和生存结果.
研究的目的:
- 评估新辅助化学免疫治疗在可切除HNSCC的患者中的有效性.
- 分析与这种治疗相关的生存结果和病理反应.
主要方法:
- 对79名可切除HNSCC.患者的回顾性分析.
- 包括接受新辅助化疗免疫疗法,随后进行激进手术的患者.
- 对临床特征和病理反应进行的相关性和生存分析.
主要成果:
- 高R0切除率 (98.7%) 和病理反应率 (53.1%).
- 一年的DFS和OS率分别为87.2%和97.4%.
- 病理反应与生存之间的积极关联;HPV阳性口腔癌显示出最好的结果. 辐射史和反应不佳是DFS的危险因素.
结论:
- 新辅助化疗免疫疗法在可切除的HNSCC中显示出高的病理反应率和低的复发率.
- 这种治疗作为这种患者群体的新标准护理具有显著的前景.
相关概念视频
Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
169
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
169
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
215
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
215
Cytotoxic T Cells-mediated Immune Response
924
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
924


